Two-stage group sequential design of the study. The null hypothesis and the alternative hypothesis were set at H0: P ≤ P0 ( = 0.3) vs. H1: P ≥ P1 (= 0.5). Since 18 of the 30 initial subjects showed responses, the clinical study was terminated at the first stage with the conclusion that Genexol-PM was effective
The study used a two-stage group sequential design [ 14 ], with 90%
power to detect a response rate of 50% and <5% chance of
continuing the trial if the response was <30% (Fig. 1 ).
The current study used a two-stage group sequential design for
sample size calculation (Fig. 1 ) [ 14 ].
Viewing this image requires a subscription. If you are a subscriber, please log in.
This image is from the article titled "Multicenter phase II trial of Genexol-PM, a Cremophor-free, polymeric micelle formulation of paclitaxel, in patients with metastatic breast cancer"
(from Breast Cancer Research and Treatment), which is copyrighted by Springer Science+Business Media, LLC. For more information on the
copyright for this image, please refer to the full image caption and to the
The image is being made available for non-commercial purposes for subscribers to SpringerImages. For more information on what you are allowed to do with this image, please see our copyright policy.
To request permissions to use any copyrighted material, please visit the source document.
Report a copyright concern regarding this image.
Log in or register to save your favorite images and download them as high-quality PowerPoint or PDF files.
Log in or register to save your search criteria.
© Springer, part of Springer Science+Business Media.
Remote Address: 18.104.22.168 Server: 18